OC-01 nasal spray, which was recently approved by the FDA, is an effective treatment for patients with varying severities of dry eye disease, according to a speaker at the European Society of Cataract and Refractive Surgeons meeting.
“Varenicline is a highly selective cholinergic agonist that stimulates natural tear production, and it is useful in the treatment of mild, moderate and severe disease,” Sheraz Daya, MD, FACP, FACS, FRCS(Ed), FRCOphth, said.
The phase 3 randomized ONSET-2 trial investigated the safety and efficacy of OC-01 (Tyrvaya (varenicline solution 0.03 mg, Oyster